Covid-19 forces Lilly to hit the brakes
As Lilly pauses much of its research owing to the coronavirus pandemic, Vantage takes a look at an estimate of the cash committed to ongoing clinical studies. Clue: it’s…
Bispecifics keep the business development fires burning
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
Go or no go? Covid-19 upstages US regulatory decisions
A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.
After Takeda endorsement Curadev’s Sting attracts Bayer
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
Clinical trial delays become reality as Covid-19 risk spreads
A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
Pfizer bulls go in search of hidden gems
As the company prepares to host its first investor day in over a decade the focus falls on underappreciated in-house assets.
Empliciti’s front-line flop underlines Darzalex’s dominance
The CS1 approach to treating multiple myeloma was once thought capable of matching CD38, but that train left the station some time ago.
Seattle could waltz in where Astra failed
Despite Astrazeneca stacking the odds in its favour Imfinzi’s Danube trial, in first-line bladder cancer, reads out negatively.
Roche move endorses Iteos’s Tigit widget
A private Belgian biotech reckons Tigit is the new PD-1, a view Roche’s progress could validate.
